medigraphic.com
ISSN 2007-6800 (Print)

2016, Number 1

<< Back Next >>

Rev Mex Traspl 2016; 5 (1)

Desensitization in kidney transplantation. Experience in the Specialty Hospital National Medical Center «La Raza» IMSS

Moreno-Ley PI, Cruz-Santiago J, Álvarez-Rangel LE, Bernáldez-Gómez G, Meza-Jiménez G, Rivera-Luna EN

Language: Spanish
References: 26
Page: 6-14
PDF size: 953.80 Kb.


ABSTRACT

Introduction: Desensitization therapy is an alternative in highly sensitized patients requiring kidney transplantation, in this group of patients waiting times and complexity of immunosuppressive therapy are increased. The increase in the number of sensitized patients is a problem in all transplantation groups. Material and methods: Ambispective, observational and descriptive study, conducted between February 2012 and August 2015 in patients at high immunological risk receiving desensitization and renal transplantation. Desensitization therapy consisted of five to seven sessions of plasmapheresis + immunoglobulin G with or without rituximab. Graft survival, renal function and acute rejection-free survival was determined at 6 and 12 months after transplantation. Statistical analysis by Kaplan-Meier method. Results: 20 patients, all kidney transplant from a living donor, with a mean follow up of 19 months were included. Graft survival was 95% at 6 and 12 months; in terms of renal function, serum creatinine at their hospital discharge at 6 and 12 months was 1.00, 1.18 and 1.36 mg/dL, respectively; glomerular filtration rate was 84.86, 61.21 and 59.68 mL/min/1.73 m2 at discharge, six months and one year respectively. Conclusions: Desensitization therapy prior to renal transplantation in patients highly sensitized allows acceptable graft survival and renal function.


REFERENCES

  1. Starzl E. History of clinical transplantation. World J Surg. 2000; 24 (7): 759-782.

  2. De-Leo-Cervantes C. Pruebas de histocompatibilidad en el Programa de Trasplantes. Rev Invest Clin. 2005; 57 (2): 142-146.

  3. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969; 280: 735-739.

  4. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE et al. Desensitization in HLA incompatible kidney recipients and survival. N Engl J Med. 2011; 365 (4): 318-326.

  5. Sanfilippo F, Vaughn WK, Bollinger RR, Spees EK. Comparative effects of pregnancy, transfusion and prior graft rejection on sensitization and renal transplant results. Transplantation. 1982; 34: 360-366.

  6. Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010; 89 (9): 1095-1102.

  7. Mancilla E. El paciente altamente hipersensibilizado. Alternativas terapéuticas para el trasplante renal. Rev Inv Clin. 2005; 57 (2): 206-212.

  8. López-Cervantes M, Rojas-Russell ME, Tirado-Gómez LL, Durán-Arenas L, Pacheco-Domínguez RL, Venado-Estrada AA et al. Enfermedad renal crónica y su atención mediante tratamiento sustitutivo en México. México, D.F.: Facultad de Medicina, Universidad Nacional Autónoma de México; 2009.

  9. Weir MR, Lerma EV. Kidney transplantation: practical guide to management. New York: Springer; 2014: p. 49.

  10. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008; 359: 242-251.

  11. Abe M, Kawai T, Futatsuyama K, Tanabe K, Fuchinoue S, Teraoka S et al. Postoperative production of anti-donor antibody and chronic rejection in renal transplantation. Transplantation. 1997; 63 (11): 1616-1619.

  12. Haririan A, Nogueira J, Kukuruga D, Schweitzer E, Hess J, Gurk-Turner C et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant. 2009; 9: 536-542.

  13. Jordan SC, Vo AA, Nast CC, Tyan D. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl. 2003; 193-198.

  14. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol. 2011; 6 (4): 922-936.

  15. Abu Jawdeh BG, Cuffy MC, Alloway RR, Shields AR, Woodle ES. Desensitization in kidney transplantation: review and future perspectives. Clin Transplant. 2014; 28: 494-507.

  16. Ronco C, Chiaramonte S, Remuzzi G. Kidney transplantation: strategies to prevent organ rejection. Contrib Nephrol. 2005; 146: 11-21.

  17. Schweitzer EJ, Wilson JS, Fernandez-Vina M, Fox M, Gutierrez M, Wiland A et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation. 2000; 70 (10): 1531-1536.

  18. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000; 70: 887-895.

  19. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004; 15: 3256-3262.

  20. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins. Am J Transplant. 2002; 2: 758-760.

  21. Rufino-Hernández JM, Cabello-Moya E, González-Posada JM, Hernández-Marrero D, Pérez-Tamajón L, Marrero-Miranda D et al. Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft. Nefrologia. 2010; 30 (2): 252-257.

  22. Taube DH, Williams DG, Cameron JS, Bewick M, Ogg CS, Rudge CJ et al. Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet. 1984; 1: 824-828.

  23. Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation. 2009; 87: 268-273.

  24. Gloor JM, DeGoey SR, Pineda AA, Moore SB, Prieto M, Nyberg SL et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant. 2003; 3 (8): 1017-1023.

  25. Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center’s experience. Transplantation. 2008; 86: 96-103.

  26. Flores-Gama F, Mondragón-Ramírez GA, Bochicchio-Riccardelli T. Desensibilización y trasplante renal. Plasmaféresis a dosis estándar en pacientes con alto riesgo inmunológico. Cir Ciruj. 2009; 77: 369-374.




2020     |     www.medigraphic.com